Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Depreciation and Depletion (2016 - 2025)

ImmunityBio (IBRX) has disclosed Depreciation and Depletion for 10 consecutive years, with $3.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Depreciation and Depletion fell 8.33% to $3.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $13.4 million, a 12.99% decrease, with the full-year FY2025 number at $13.4 million, down 13.55% from a year prior.
  • Depreciation and Depletion was $3.3 million for Q4 2025 at ImmunityBio, down from $3.4 million in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $4.6 million in Q4 2022 to a low of $3.3 million in Q1 2025.
  • A 5-year average of $3.8 million and a median of $3.9 million in 2022 define the central range for Depreciation and Depletion.
  • Biggest YoY gain for Depreciation and Depletion was 73.91% in 2021; the steepest drop was 37.93% in 2021.
  • ImmunityBio's Depreciation and Depletion stood at $3.6 million in 2021, then increased by 27.78% to $4.6 million in 2022, then dropped by 13.04% to $4.0 million in 2023, then decreased by 10.0% to $3.6 million in 2024, then fell by 8.33% to $3.3 million in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Depreciation and Depletion are $3.3 million (Q4 2025), $3.4 million (Q3 2025), and $3.4 million (Q2 2025).